Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical firm Uluru has received a notice of allowance from the US Patent and Trademark Office for its nanoparticle aggregate patent that covers the underlying science behind the nanoparticle aggregate technology.
Subscribe to our email newsletter
On issuance, the patent will expire in 2022. The company said that the subsequently filed patent applications which broaden its patent position could extend the patent life for the wound care and breast implant product portfolios until the end of 2026.
Kerry Gray, president and CEO of Uluru, said: “This notice of allowance is an important step in securing intellectual property protection for the range of products we anticipate developing from our nanoparticle aggregate technology. To further secure our patent position we have also filed additional patents to protect the wound care, breast implant and dermal filler applications of the technology.”